Novaliq targets uveitis with EyeSol-based NOV05: Can topical tacrolimus go intraocular?
Novaliq’s NOV05 enters Phase 2 trials for anterior uveitis. Can it deliver steroid-free, topical relief for inner-eye inflammation? Find out what’s next.
How United Therapeutics is betting on scaffold-based liver support in high-mortality ALF
United Therapeutics’ miroliverELAP showed positive phase 1 safety results in acute liver failure. Find out what this could mean for future liver support strategies.
Why Aviva Bio’s deuterated testosterone may change hormone therapy for women
Aviva Bio’s AVA‑291 receives FDA development feedback for women’s testosterone therapy. See what makes it safer and what happens next in clinical trials.
Genethon advances Duchenne gene therapy trial while licensing Pompe tech to Bayer’s AskBio
Genethon advances gene therapies for Duchenne and Pompe disease. Find out what its nonprofit model and AskBio licensing deal mean for rare disease care.
Eisai and Biogen advance injectable Alzheimer’s therapy with FDA fast-track decision
FDA fast-tracks Eisai’s LEQEMBI IQLIK for at-home Alzheimer’s care. Find out what this means for patients, payers, and delivery models today.
Landmark FDA nod gives MSC developers long-awaited quality benchmark for clinical use
The FDA has recognized Tasly’s 3P assay as the first quality control standard for MSCs. Find out what this changes for developers and regulators.
Argo Biopharma’s RNAi therapy targets Lp(a): What Phase 2b with Novartis could prove
Novartis advances Argo Biopharma’s BW-20829 into Phase 2b to target lipoprotein(a). Explore what this means for RNAi adoption in cardiovascular therapeutics.
Is oral GLP-1 finally viable? Inside Ascletis Pharma’s U.S. trial for ASC30
Ascletis starts U.S. Phase II trial of ASC30 in type 2 diabetes. Find out what this oral GLP-1R agonist could mean for the future of metabolic therapies.
FDA priority review for Leqembi Iqlik could transform Alzheimer’s drug initiation at home
Leqembi Iqlik gets FDA Priority Review for at-home Alzheimer’s treatment initiation. Find out what this could mean for patients, payers, and the care model.
Moderna and Merck’s mRNA-4157 combo shows durable benefit in resected high-risk melanoma
Moderna, Inc. and Merck have reported five-year follow-up results from the Phase 2b KEYNOTE-942 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational individualized mRNA-based neoantigen therapy, in combination with pembrolizumab (KEYTRUDA) in patients with resected high-risk stage III or IV melanoma. The combination demonstrated a 49 percent reduction in the risk of recurrence or […]